Antibody-Drug Conjugates in Brain Metastases from Solid Tumors: Current Status,Therapeutic Potential,and Future Perspectives
10.3870/j.issn.1672-0741.26.05.023
- VernacularTitle:抗体药物偶联物在实体瘤脑转移中的应用:现状、治疗潜力与未来展望
- Author:
Yunfei DAI
1
;
Jing FEI
2
Author Information
1. School of Medicine,Shihezi University,Shihezi 832000,China
2. Department of Oncology,First Affiliated Hospital of Shihezi University,Shihezi 832000,China
- Publication Type:Journal Article
- Keywords:
antibody-drug conjugates;
brain metastases;
blood-brain barrier;
blood-tumor barrier;
radiation necrosis;
bystander effect;
leptomeningeal disease
- From:
Acta Medicinae Universitatis Scientiae et Technologiae Huazhong
2026;55(4):597-605
- CountryChina
- Language:Chinese
-
Abstract:
Brain metastases are a common and clinically challenging manifestation of solid tumors and are generally associated with poor prognosis and limited systemic treatment options.Effective intracranial drug delivery remains difficult because of the blood-brain barrier,the blood-tumor barrier,and the distinct immune microenvironment of brain metastases.Antibody-drug conjugates(ADCs),consisting of a monoclonal antibody,a chemical linker,and a cytotoxic payload,have shown substantial clinical value in multiple solid tumors.Accumulating evidence of intracranial activity in patients with brain metastases from breast cancer,lung cancer,and other solid tumors suggests that ADCs may provide new opportunities for systemic treatment in this setting.This review summarizes the potential mechanisms of action,clinical evidence,safety considerations,and future research directions of ADCs for brain metastases from solid tumors,aiming to inform optimization of therapeutic strategies for this patient population.